Multiple types of cancer including colorectal, breast, ovarian, lung, liver
PIK3CA somatic mutations have been frequently detected in advanced solid tumors. Mutations occur mainly within the helical domain (exon 9) and the kinase domain (exon 20). Roughly 20-30% of colorectal (CRC)1, and breast cancers2, 3 have been estimated to be PIK3CA positive. A significant subset of ovarian, lung, and gastric cancers have also been reported to have PIK3CA mutations1, 4. Studies have associated hotspot PIK3CA mutations with responsiveness to PI3K pathway inhibitors5, 6, 7. PIK3CA mutations have also been associated with resistance to HER2 (ERBB2) targeted therapies in HER2+ breast cancers 8, 9. For EGFR mutant lung cancers, PIK3CA mutations have been found in ~5% of cases with acquired resistance to EGFR inhibitors10.
To open a printable assay summary in a new window, click the link below.
PIK3CA NGS Assay Summary
(Targeted analysis for 97 cancer hotspot mutations in the PIK3CA gene by next generation sequencing)
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)
- Samuels Y, et al. Science. 2004 Apr 23;304(5670):554
- Saal LH, et al. Cancer Res. 2005 Apr 1;65(7):2554-9.
- Stemke-Hale K, et al. Cancer Res. 2008 Aug 1;68(15):6084-91
- Campbell IG et al. Cancer Res. 2004 Nov 1;64(21):7678-81.
- O'Brien C, et al. Clin Cancer Res. 2010 Jul 15;16(14):3670-83
- Bendell JC, et al. J Clin Oncol. 2012 Jan 20;30(3):282-90.
- Janku F, et al. Mol Cancer Ther. 2011 Mar;10(3):558-65
- Eichhorn PJ et al. Cancer Res. 2008 Nov 15;68(22):9221-30
- Berns K, et al. Cancer Cell. 2007 Oct;12(4):395-402
- Sequist LV, et al. Sci Transl Med. 2011 Mar 23;3(75):75ra26